Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable…

Overview of attention for article published in Cancer & Metabolism, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#49 of 214)
High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter: 12 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 10,520 followers.

"Safety,tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: ..." co-authored by Dr K Popuri ht

12 Sep 2023

Reply Repost Favourite

RT @JoeIppolitoLab: 🚨New lab publication!🚨Translational cancer metabolism. Phase 1b Sodium Glucose CoTransporter 2 inhibitors (SGLT2i) to m…

24 May 2023

Reply Repost Favourite

RT @JoeIppolitoLab: 🚨New lab publication!🚨Translational cancer metabolism. Phase 1b Sodium Glucose CoTransporter 2 inhibitors (SGLT2i) to m…

24 May 2023

Reply Repost Favourite

RT @VoronoiHealth: https://t.co/PR75sm7wBJ

24 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.